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Human donor cells, including neurally directed embryonic
stem cells and induced pluripotent stem cells with the
potential to be used for neural transplantation in a range
of neurodegenerative disorders, must first be tested
preclinically in rodent models of disease to demonstrate
safety and efficacy. One strategy for circumventing the
rejection of xenotransplanted human cells is to desensitize
the host animal to human cells in the early neonatal period
so that a subsequent transplant in adulthood is not
immunorejected. This method has been robustly validated
in the rat, but currently not in the mouse in which most
transgenic models of neurodegeneration have been
generated. Thus, we set out to determine whether this
could be achieved through modification of the existing rat
protocol. Mice were inoculated in the neonatal period with
a suspension of human embryonic cortical tissue of varying
cell numbers, and received a subsequent human
embryonic cortical tissue cell transplant in adulthood.
Graft survival was compared with those in mice
immunosuppressed with cyclosporine A and those
receiving allografts of mouse whole ganglionic eminence
tissue. Poor survival was found across all groups,
suggesting a general problem with the use of mouse hosts
for testing human donor cells. NeuroReport 24:1010–1015
c 2013 Wolters Kluwer Health | Lippincott Williams &
Wilkins.
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Introduction
Preclinical testing of human donor cells requires trans-
plantation into animal (most commonly rodent) models of
disease to confirm safety and assess functional efficacy.
For example, neurotoxic lesion models of Huntington’s
disease (HD) are commonly used as they closely model
some key features of the disease, such as relevant cell loss
and histological changes. These models are ideal for
assessing the functional effect of transplanted cells on
lesion-induced deficits observed on motor and cognitive
tasks. However, genetic models such as transgenic mice
may be a more relevant model for the study of neural
transplantation as they more accurately reflect the
progressive disruption to specific circuitry in the brain [1].
Several HD mouse models exist, expressing either
insertions of the full-length HD gene or the expanded
CAG repeat fragment [2–5], and these are substantially
more numerous and well-established than similar models
in the rat [6,7].
Six weeks after striatal allografts of wild-type mouse
tissue into the adult R6/2 mouse model of HD, graft
survival and marginal behavioural improvements have
been observed [8], but transplants of immortalized
human striatal neural stem cells into the same host
yielded very small grafts and no behavioural improve-
ment [9], suggesting that the tissue was subjected to
immunorejection. Indeed, xenogeneic tissue transplanted
into the rodent brain appears to be rejected from 1–2
weeks; thus, some form of immunosuppression is
required to permit graft survival. Conventional methods
include the use of immunosuppressant drugs, including
cyclosporine A (CsA), or immunocompromised hosts, for
example, SCID or Rag2-deficient mice. However, side
effects of drugs such as CsA lead to termination of
experiments before human cells have had time to fully
differentiate and integrate within the host brain, thus
preventing full functional assessment of donor cells. In
addition, immunocompromised hosts are particularly
sensitive to infection, and do not withstand a full battery
of behavioural tests. We have previously demonstrated
that neonatal desensitization to human tissue promotes
long-term survival of human neural transplants in the
rat [10], which has since been confirmed by
others [11,12], although to date success has not been
demonstrated in the mouse.
Our primary aim was therefore to determine whether
mice could be successfully desensitized in the neonatal
period to human foetal neural tissue to allow long-term
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assessment of human donor cell survival and differentia-
tion. This would permit full behavioural assessment of
transplant effects and a long-term assessment of the cells
in vivo to determine whether they are affected by the
underlying disease processes. Survival of human xeno-
grafts in desensitized mouse hosts, either quinolinic (QA)
acid lesioned or unlesioned, was compared with those of
CsA immunosuppressed or untreated hosts. A further
group of nonimmunosuppressed or CsA-treated mice
received mouse allografts. We observed poor and variable
survival of transplants across all conditions. These data
suggests a general problem with the use of mouse hosts
for both neural xenografts and allografts, and implies the
need for optimization of mouse transplant protocols
before it can be determined whether desensitization
may be successfully achieved in this species.
Materials and methods
Animals
All animal experiments and surgical procedures were
conducted under the UK Animals (Scientific Procedures)
Act 1986, and subjected to local ethical review and
relevant personal, project and institutional licences. A
total of 163 CD-1 mice (79 male, 84 female) were
included as transplant hosts or lesion only controls. Sixty
mice were purchased as adults (Harlan, Bicester, UK) and
13 pregnant dams were used to produce neonates for
desensitization and embryos for mouse tissue transplants.
Pregnant dams were housed individually and adult mice
following weaning and on arrival were housed in same sex
groups of two to four mice per cage with experiments
beginning in adults weighing 20–25 g, at around 8–10
weeks of age.
Dissection and dissociation of human embryonic
cortical tissue and mouse whole ganglionic eminence
Human cortical tissue (ranging from 7–11 weeks gesta-
tion) was collected from the donation of the products of
elective terminations of pregnancy. All tissue was donated
through the South Wales Initiative for Foetal Tissue
Transplantation (SWIFT) with ethical approval from the
Bro Taf Local Research Ethics Committee. Human and
mouse tissue for neonatal desensitization and transplan-
tation was collected, dissected and dissociated as
described previously [13,14]. Briefly, human foetal tissue
was collected from medical terminations of pregnancy
into Hibernate E medium (Gibco, Paisley, UK) before
dissection and collection of human embryonic cortical
(hCTX) tissue. For allograft experiments, E14 CD-1
mouse embryos were collected and mouse whole gang-
lionic eminence (mWGE) dissected for dissociation as
with human tissue. Tissue was digested in trypsin at 371C
and washed before resuspending in Dulbecco’s modified
Eagle medium (DMEM)/F12 (with 5% penicillin strep-
tomycin) to generate a single cell suspension. Viability of
all cell suspensions was determined by trypan blue
exclusion counting before injection and rejected if
viability was lower than 80%. After counting, cell
suspensions were made up to relevant concentrations
for injection in 1–2 ml DMEM/F12.
Neonatal desensitisation
Pregnant CD-1 mice (10) were housed individually until
they gave birth. Pups were injected neonatally into the
peritoneal cavity (i.p.) with a cell suspension of hCTX
between postnatal days 0–3 (P0–3). As standard, mice
were injected with 1 ml of cell suspension containing
1 105 cells in DMEM/F12 unless otherwise specified.
In the case of an injection of greater than 5 105 cells,
suspensions were prepared in a volume of 2 ml. Pups were
separated briefly from their mothers for intraperitoneal
injection of cells, then returned and left until weaning at
B28 days.
Surgical procedures
All surgical procedures were performed under isoflurane
anaesthesia induced in an induction chamber with 5%
isoflurane in oxygen at 0.8 l/min. Anaesthesia was
maintained by passive inhalation of isoflurane
(1.5–2.5%) in a mixture of oxygen (0.8 l/min) and nitrous
oxide (0.4 l/min).
Adult CD-1 mouse hosts either received a unilateral QA
lesion to the right striatum, or the host brain was left
intact. The skull was exposed, a small burr hole drilled
above the right striatum at 0.8mm rostral to bregma (AP)
– 2.0mm lateral to midline (L) and – 3.0–2.8mm ventral
from dura (V). QA was injected through a cannula
attached to a 10 ml Hamilton syringe driven by a
mechanical pump. 0.75 ml of 0.09M QA dissolved in
0.1M phosphate buffer was injected over 6min, the
needle was then left in place for 3min to prevent reflux
of toxin up the needle tract. The incision was sutured and
animals were administered subcutaneous injections of
0.5ml saline glucose (using a 1ml syringe and 26G
needle), 5 ml Metacam and an intramuscular injection of
30 ml diazepam (both measured and administered using a
300 ml insulin syringe) into the upper leg before transfer
to a warm recovery chamber. Hosts then received
transplants of hCTX or mWGE, from 2 days to 2 months
post-lesion, to the same coordinates into the intact or
lesioned striatum to a total of 3 105 or 5 105 cells
in 2 ml.
Most animals receiving xenotransplants that were not
desensitized received daily intraperitoneal injections of
CsA (Sandimmun, 10mg/kg; Novartis, Hampshire, UK)
for the duration of the experiment, starting 1 day prior to
transplantation.
Histology and immunohistochemistry
Mouse hosts were transcardially perfused 6–12 weeks
after transplantation with 1.5% paraformaldehyde, and
brains collected for histological analysis. Brains were
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sectioned at 40 mm on a freezing sledge microtome and
stored at 41C in Tris-buffered saline with 0.2% azide, or at
– 201C in antifreeze. 1 : 12 series were mounted for Nissl
staining with cresyl violet, and additional 1 : 12 series
stained as free-floating sections for immunohistochem-
istry using anti-HuNu (1 : 1000; Millipore, Molsheim,
France) and anti-Iba1 (1 : 8000; Wako, Neuss, Germany)
primary antibodies and biotinylated secondary antibodies
(anti-mouse and anti-rabbit, 1 : 200; Vector, Peterborough,
UK). Immunohistochemical staining protocols were the
same for all antibodies with the exception of HuNu,
which in some cases was biotinylated using a biotin
conjugation kit to avoid the use of an anti-mouse
secondary antibody and lower background staining
(Lightning Link Biotin Conjugation Kit; Innova Bio-
sciences, Cambridge, UK). Diaminobenzidine was used
for visualization of all antibody staining. Small modifica-
tions were made to the protocol to attempt to improve
reliable labelling of grafted cells, which is discussed
further in the results section. Grafts were visualized
under a Leica DRMBE light microscope (Leica Micro-
systems, Milton Keynes, UK). Images were captured
using a Leica DFC420 camera and Leica Application
Suite image analysis software (Leica Microsystems).
Images were processed using Adobe Photoshop (Adobe
Systems Incorporated, San Jose, California, USA).
Results
To identify surviving grafts in transplanted hosts, sections
from all animals were initially stained with the Nissl stain
cresyl violet (Fig. 1a, b, e, f, and i–l). To confirm the
presence of transplanted human cells, tissue sections
from xenografted animals were immunohistochemically
stained with HuNu (Fig. 1c and g). Staining of Nissl
bodies with cresyl violet showed dense staining in the
grafted area on a number of sections, suggestive of
surviving human grafts. However, the presence of
transplanted cells could not be convincingly detected
with human specific antibody staining. In these cases
microglial marker staining with Iba1 (Fig. 1d and h)
revealed the presence of dense activated microglia
corresponding to the grafted area. Sections showing such
inconsistencies between cresyl violet and HuNu staining
were therefore not considered to contain healthy surviv-
ing grafts but rather grafts that were undergoing
rejection.
Numbers of surviving healthy transplants as detected by
these criteria are outlined in Table 1. Low levels of graft
survival were found across all groups in allografts as well
as xenografts, even in desensitized and CsA-treated
groups, irrespective of the time of assessment after
transplantation, and time between lesion and transplant.
A small number of large surviving human grafts could be
confidently detected, mainly in CsA-treated hosts (50%),
with a small number from desensitized animals (14%).
A number of transplants in CsA-treated animals were very
dense and vascularized, with a large amount of microglia
staining (Fig. 1i and j). Surviving mouse allografts were
very small, indeed most consisted of a narrow column of
cells. Moreover, due to the lack of an appropriate
antibody or specific donor cell label, they could not be
detected with the same degree of confidence as human
transplants, and therefore survival rate may have been
overestimated. The majority of sections in both allograft
and xenograft animals showed either no staining or an
area of dead cells (with haemosiderin and nonspecific
antibody uptake) and scarring. In addition, the majority of
sections showed dense microglial staining with Iba1.
Because of the lack of surviving grafts, statistical analysis
of data was not undertaken. However, as can be seen
in Fig. 1m, desensitization did not provide any improve-
ment in promoting survival of human transplants and the
percentage of surviving grafts was comparable with that of
untreated animals (16 and 15%, respectively). CsA
treatment provided a slight improvement in transplant
survival; however, this still only reached 50%, with no
improvements observed from transplants of higher
numbers of donor cells (5 105 vs. 3 105).
Discussion
To promote the survival of human neural transplants in
preclinical models of disease we have previously demon-
strated that rat hosts may be desensitized to human
foetal tissue in the neonatal period, allowing survival of a
human striatal xenograft for sufficient time to permit
assessment of functional efficacy [10]. To date, successful
translation of this method from the rat to the mouse has
not been achieved. In this study, we aimed to desensitize
mouse hosts to human foetal tissue following the same
protocols as used previously. Host animals were initially
desensitized with 1 105 hCTX cells in the neonatal
period, or treated with CsA daily following transplanta-
tion of 3 105 hCTX, or mWGE cells to the right
lesioned or intact striatum. Survival in both desensitized
and CsA-treated animals was low. In subsequent trans-
plants, 5 106 hCTX cells were transplanted but this did
not improve graft survival, and may have caused over-
crowding and promoted rejection.
Neonatal (and in utero) tolerance induction has been des-
cribed for decades using a similar method to that
described here [15,16]. Previous work shows the induc-
tion of tolerance to allogeneic skin grafts following an
injection of spleen [17,18], liver [19] or bone marrow
cells [20], although less success has been observed in the
case of xenografts [21]. Other examples of the induction
of neonatal tolerance in mice have used large numbers of
spleen cells (e.g. 1.5 107 – 1 108) [22,23] injected
neonatally and studies suggest the administration of
larger cell numbers increases the potential of inducing
tolerance [17,23]. As desensitization in our study did not
promote neuronal graft survival in our initial experi-
ments, we used increasing numbers of cells to induce
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desensitization in subsequent experiments; however,
this did not result in improved graft survival. Indeed,
there was a suggestion that fewer transplants survived in
mice desensitized with the highest numbers of cells.
Animals were transplanted at varying times post-lesion to
identify whether any improvements in graft survival could
be found, as previous data has suggested a shorter time
between lesion and transplant could yield better re-
sults [24]. No differences were found in groups receiving
earlier or later transplants; thus, data are discussed
together. In addition to poor graft survival in desensitized
hosts, CsA treatment did not promote survival to a
reliable degree with only 50% of transplants surviving and
poor, potentially rejecting, transplants observed in many
hosts. However, hosts transplanted with mouse tissue
from donors of the same strain did not show consistent
survival, even when treated with CsA. Concurrent
transplants carried out on desensitized rat hosts have
yielded up to 100% survival of human striatal transplants
(V.H. Roberton, C.M. Kelly, unpublished data).
These findings are not exclusive to the experiments
presented here; other data from our lab reveals similar
difficulty in achieving success in mouse transplants,
including mouse allografts (V.H. Roberton, A.E. Evans,
unpublished observations). Transplants in the mouse
brain are commonly found to be substantially smaller than
those surviving in the rat, even allowing for the
differences in host brain size [9,13]. Promoting survival
of human tissue transplants in the mouse has been shown
to be a challenge even when using conventional methods
of immunosuppression, that generally promote survival in
Fig. 1
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rat transplants. Moreover, recent data suggests the mouse
brain is less tolerant to cell transplants than the rat, with
xenotransplant work being carried out in SCID [25] or
Rag2 – / – host mice [26]. In addition, transplants into
neonatal SCID mice or neonates crossed with Rag2 – / –
mice have been used to extend survival of human
cells [27,28], suggesting that the problem with survival
of xenografts in the mouse brain is a widespread issue.
The reason for poorer transplant survival in the mouse
host as compared with the rat is currently unclear. It may
be related to the mouse host response to human tissue
specifically, however, poor allograft survival suggests this
is not the case. Alternatively, the mouse immune system
may be more sensitive than that of the rat. Without
achieving consistent successful transplant survival using
standard strategies it is not possible to test the suitability
of neonatal desensitization as a method of preventing
rejection of human donor cells in the mouse brain.
In all transplant groups small numbers of large transplants
were found to survive. We cannot exclude the possibility
that this is due to some hosts potentially receiving larger
quantities of cells due to uneven preparation of cell
suspensions or blockage of transplant syringes. However,
this seems unlikely given the high levels of survival of
transplants in rat hosts using the same transplant
protocols [10]. Furthermore, our observations of a strong
microglial response to human transplants in the mouse
striatum suggest the likelihood of an increased immune
response to xenografted (and possibly also to allografted)
cells in the mouse compared with the rat.
Conclusion
We were unable to validate the success of neo-
natal desensitization of mouse hosts to human foetal
tissue, specifically to striatal transplants of hCTX tissue.
However, this could not be attributed specifically to the
desensitization strategy and appeared to occur across all
conditions, including with the use of conventional
immunosuppression in the form of daily treatment with
CsA. The fact that striatal allografts also showed poor
survival even over relatively short survival times suggests
that the adult mouse brain is a more hostile environment
for graft placement than that of the rat. Indeed, the
validation of the desensitization approach, as well as
the use of mouse models for preclinical assessment, will
have to await a better understanding of the mechanisms
underlying poor graft survival, and improved strategies to
address this issue.
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